Hear from Prof Harry Sokol why gut microbiota are so important for human diseases and their treatments

The 14th EACPT Congress was held from 29th June to 2nd July in 2019 in Stockholm as a partnership between the EACPT and the Swedish Society for Pharmacology, Clinical Pharmacology and Therapeutics.

The term gut microbiota describes the population of microbes living in our intestines. Gut microbiota are being increasingly recognised as important contributors to a wide range of human diseases, from disorders of the gut to cancers and neurological disease.
Gut microbiota also contribute to drug response and to risk of adverse drug effects. Gut microbiota also provide a source of potential treatments.

In this short video you can hear keynote EACPT Congress speaker Professor Harry Sokol from Paris discuss the importance for clinical pharmacologists, other health professionals and patients of understanding emerging key roles for gut microbiota in serious diseases and their treatments.

Discussants  
Professor Harry Sokol, Hôpital Saint-Antoine and Sorbonne University, Paris, France
in discussion with
Professor Tabassome Simon, EACPT Past-President

The next EACPT Congress
The next EACPT biennial congress will be held in Athens in June 2019. The programme will provide an international scientific and educational forum for discussion of clinical pharmacology and therapeutics, including personalised pharmacotherapy. See more on our website.

Joining the EACPT
Anyone from anywhere in the world with a professional interest in clinical pharmacology and therapeutics can now join the EACPT as an Individual Associate member.

Membership benefits include:
* Discounted registration fees for EACPT meetings
* Online subscription to the EACPT Official journal: the European Journal of Clinical Pharmacology
* Access to the EACPT’s worldwide network of Individual Associate Members
* Active involvement in EACPT 

25th Anniversary
The EACPT was founded 25 years ago and now includes as members all major national organisations for clinical pharmacology in Europe, as well as organisations from further afield internationally. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth. Find out more about the EACPT ...

Future EACPT Congresses

2021  Athens

2023  Rotterdam

2025  Helsinki

2013 EACPT Scientific Award for new treatment approach for Parkinson's disease

The EACPT is delighted to announce that the 2013 EACPT Scientific Award goes to Dr David Devos from the Department of Medical Pharmacology at the Université Lille Nord de France. The EACPT Scientific Award is for the report by Dr Devos about a new approach to treating Parkinson's disease. 

The paper, for which Dr Devos was corresponding author, was published in the July 2012 issue of

Dr David Devos

the high impact international journal -  Lancet Neurology, entitled:

'Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial.'

The prize, which includes a 2000 € award, will be presented to Dr Devos at the 11th EACPT Congress in Geneva 28th - 31st August 2013.

David Devos obtained his Doctor of Neurology and Doctor of Neuroscience degrees from the University of Lille, France. Between 2002 and 2010, he worked as a hospital physician in the Department of Neurology of the Centre Hospitalier Universitaire of Lille, where he is now associate professor in medical pharmacology (Lille Nord de France University, EA1046/EA4559).
 His main research interest is in developing new symptomatic and disease-modifying strategies in neurodegenerative diseases, such as Parkinson’s disease, amyotrophic lateral sclerosis, dementia and cerebellar ataxia. His researches are mainly based upon clinical trials but also include preclinical, translational and clinical studies in neuropsychopharmacology.

The EACPT Scientific Award is for the best scientific paper on a topic relevant to clinical pharmacology and therapeutics published by a European clinical pharmacologist over the period between EACPT congresses, based on nominations by the EACPT Council. The award has a value of 2000 €. Criteria are scientific quality, broader impact in science, and the importance of the work in the context of healthcare delivery.

The EACPT was founded 20 years ago and now includes all national organisations for clinical pharmacology in Europe. The EACPT aims to provide educational and scientific support for the more than 4000 individual professionals interested in clinical pharmacology and therapeutics throughout the European region, with its congresses attended by a global audience. The EACPT also advises policy makers on how the specialty can contribute to human health and wealth.

Official EACPT journal: Clinical Therapeutics 

More about the 11th EACPT Congress in Geneva.

More about the EACPT.